Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKinsey
Medtronic
Baxter
Merck

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR ASMANEX HFA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Asmanex Hfa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00394355 ↗ Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418) Completed Merck Sharp & Dohme Corp. Phase 4 2006-09-01 This is a randomized, multi-center, parallel-group, active-controlled, double-blind study evaluating the effects of mometasone furoate (MF) dry powder inhaler (DPI) on bone mineral density (BMD) in subjects with asthma. The mean percent change in lumbar spine BMD from the averaged baseline value (the average of the two scan results prior to treatment) to the endpoint of treatment time point (the average of the last two valid post-baseline scan results during treatment) for the comparison of MF DPI 400 mcg daily in the evening versus montelukast (ML) 10 mg daily in the evening.
NCT00442117 ↗ A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880) Completed Merck Sharp & Dohme Corp. Phase 3 2007-06-01 This study will be an open-label, parallel-group comparison of Mometasone Furoate Dry Powder Inhaler (MF-DPI) 200 mcg once daily in the evening with two puffs vs. Budesonide Dry Powder Inhaler (BUD-DPI) 200 mcg twice daily with two puffs each time in patients previously treated with inhaled corticosteroids (ICS) or without ICS with diagnosed mild persistent or moderate persistent asthma (classified as Global Initiative For Asthma, 2005) in the previous 4 weeks. The primary efficacy endpoint is percent change from baseline in FEV1.
NCT00442351 ↗ Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED) Terminated Merck Sharp & Dohme Corp. Phase 4 2006-09-01 This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily (QD) in the evening (PM) compared with "Asmanex" Placebo QD PM for 12 weeks. Efficacy will be measured for the changes in forced expiratory volume in 1 second (FEV1) from baseline to the end of treatment period (Week 12 or end of the study).
NCT00461812 ↗ A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma Terminated Schering-Plough Phase 4 2007-04-01 The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in control of mild persistent asthma? The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50, when measured by this standard methodology (methacholine bronchoprovocation) in subjects with mild persistent asthma.
NCT00461812 ↗ A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma Terminated Johns Hopkins University Phase 4 2007-04-01 The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in control of mild persistent asthma? The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50, when measured by this standard methodology (methacholine bronchoprovocation) in subjects with mild persistent asthma.
NCT00521599 ↗ A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828) Completed Merck Sharp & Dohme Corp. Phase 4 2007-05-01 This study is a placebo-controlled study with 8-weeks of double-blind treatment of mometasone furoate dry powder inhaler (MF DPI) 200 mcg twice daily (BID) using two different inhalers, preceded by the Screening Period and by 2 weeks of open-label treatment with one inhalation of MF DPI 200 mcg twice daily in corticosteroid-dependent asthmatic subjects. The objective of this study is to evaluate the therapeutic equivalency of the 100 mcg and 200 mcg MF DPIs when providing the same total daily dose (400 mcg/day).
NCT00711165 ↗ Mometasone and Markers of Airway Inflammation Completed Schering-Plough Phase 4 2005-08-01 A post-marketing study to look at the effects of Asmanex on markers of airway inflammation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Asmanex Hfa

Condition Name

Condition Name for Asmanex Hfa
Intervention Trials
Asthma 11
Spinal Cord Injury 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Asmanex Hfa
Intervention Trials
Asthma 10
Wounds and Injuries 1
Spinal Cord Injuries 1
Inflammation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Asmanex Hfa

Trials by Country

Trials by Country for Asmanex Hfa
Location Trials
United States 18
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Asmanex Hfa
Location Trials
Florida 2
New York 2
New Jersey 1
Nebraska 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Asmanex Hfa

Clinical Trial Phase

Clinical Trial Phase for Asmanex Hfa
Clinical Trial Phase Trials
Phase 4 7
Phase 3 3
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Asmanex Hfa
Clinical Trial Phase Trials
Completed 8
Terminated 2
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Asmanex Hfa

Sponsor Name

Sponsor Name for Asmanex Hfa
Sponsor Trials
Merck Sharp & Dohme Corp. 7
Schering-Plough 2
Milton S. Hershey Medical Center 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Asmanex Hfa
Sponsor Trials
Industry 11
Other 5
U.S. Fed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Boehringer Ingelheim
Baxter
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.